<DOC>
	<DOCNO>NCT02905253</DOCNO>
	<brief_summary>The primary purpose first-in-man study investigate whether AC-084 safe well-tolerated orally administer single- multiple-ascending dose healthy adult</brief_summary>
	<brief_title>A Study Evaluate AC-084 Safe , Its Fate Body Well Its Potential Effects Body Healthy Subjects</brief_title>
	<detailed_description>The study design three part , A , B C Part A : single-center , double-blind , randomize , placebo-controlled , single ascend dose Part B : single-center , double-blind , randomize , placebo-controlled , multiple ascend dose Part C : single-center , open-label , single dose CYP2C9 poor metabolizers</detailed_description>
	<criteria>Signed informed consent local language prior studymandated procedure Healthy male subject Part A , healthy male female subject Part B Part C age 18 55 year ( inclusive ) screen No clinically significant finding physical examination screen Body mass index ( BMI ) 18.0 28.0 kg/m2 ( inclusive ) screen CYP2C9 poor metabolizers ( Part C ) History clinical evidence disease and/or existence surgical medical condition might interfere absorption , distribution , metabolism excretion study treatment ( appendectomy herniotomy allow , cholecystectomy allow ) Previous history fainting , collapse , syncope , orthostatic hypotension , vasovagal reaction Treatment substance know induce CYP enzyme drug metabolism within 30 day prior first study treatment administration Any circumstance condition , , opinion investigator , may affect full participation study compliance protocol Known allergic reaction hypersensitivity study treatment drug class , excipients For Part A Part B , CYP2C9 poor metabolizers enrol cohort dose single multiple dose 500 mg high ACT774312 ( confirm genotyping enrollment )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>